Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH.

Autor:	Gilling PJ; Tauranga Urology Research, Tauranga, New Zealand., Barber N; Frimley Park Hospital., Bidair M; San Diego Clinical Trials, San Diego, California, USA., Anderson P; Royal Melbourne Hospital, Melbourne, Australia., Sutton M; Houston Metro Urology, Houston, Texas, USA., Aho T; Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, United Kingdom., Kramolowsky E; Virginia Urology, Richmond, Virginia, USA., Thomas A; Princess of Wales Hospital, Bridgend, Wales, United Kingdom., Kaufman RP Jr; Albany Medical College, Albany, New York, USA., Badlani G; Wake Forest School of Medicine, Winston-Salem, North Carolina, USA., Plante M; University of Vermont Medical Center, Burlington, Vermont, USA., Desai M; University of Southern California, Institute of Urology, Los Angeles, California, USA., Doumanian L; University of Southern California, Institute of Urology, Los Angeles, California, USA., Te AE; Weill Cornell Medical College, New York, New York, USA., Roehrborn CG; Department of Urology, UT Southwestern Medical Center, University of Texas Southwestern, Dallas, Texas, USA.
Jazyk:	angličtina
Zdroj:	The Canadian journal of urology [Can J Urol] 2022 Feb; Vol. 29 (1), pp. 10960-10968.
Abstrakt:	Introduction: To determine if Aquablation therapy can maintain long term effectiveness in treating men with moderate to severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with a baseline prostate volume between 30 and 80 mL at 5 years compared to TURP. Materials and Methods: In a double-blinded, multicenter prospective randomized controlled trial, 181 patients with moderate to severe LUTS secondary to BPH underwent TURP or Aquablation. The primary efficacy endpoint was reduction in International Prostate Symptom Score (IPSS) at 6 months. The primary safety endpoint was the occurrence of Clavien-Dindo persistent Grade 1 or Grade 2 or higher operative complications at 3 months. The assessments included IPSS, Male Sexual Health Questionnaire (MSHQ), International Index of Erectile Function (IIEF) and uroflow (Qmax). The patients were followed for 5 years. Results: The primary safety endpoint was successfully achieved at 3 months where the Aquablation group had a lower event rate than TURP (26% vs. 42%, p = .0149 for superiority). Procedure-related ejaculatory dysfunction was lower for Aquablation (7% vs. 25%, p = .0004). The primary efficacy endpoint was successfully achieved at 6 months, where the mean IPSS decreased from baseline by 16.9 points for Aquablation and 15.1 points for TURP; the mean difference in change score at 6 months was 1.8 points larger for Aquablation (p < .0001 for non-inferiority, p = .1346 for superiority). At 5 years, IPSS scores improved by 15.1 points in the Aquablation group and 13.2 points in TURP (p = .2764). However, for men with larger prostates (≥ 50 mL), IPSS reduction was 3.5 points greater across all follow up visits in the Aquablation group compared to the TURP group (p = .0123). Improvement in peak urinary flow rate was 125% and 89% compared to baseline for Aquablation and TURP, respectively. The risk of patients needing a secondary BPH therapy, defined as needing BPH medication or surgical intervention, up to 5 years due to recurrent LUTS was 51% less in the Aquablation arm compared to the TURP arm. Conclusions: The improvement in net health outcomes from Aquablation therapy outweigh those offered by a TURP when considering the efficacy benefit along with the lower risk of needing a secondary BPH therapy and avoiding retrograde ejaculation. Following Aquablation therapy, symptom reduction and uroflow improvement at 5 years have shown to be durable and consistent across all years of follow up compared to TURP. Larger prostates (≥ 50 mL) demonstrated a larger safety and efficacy benefit for Aquablation over TURP.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu